Brian Gastman MD, discusses how findings from CheckMate76K contributed to the rationale for a biomarker analysis in that trial’s patient population, key findings from this biomarker analysis, and how these findings may inform further research regarding the benefits of immunotherapy in earlier-stage disease.
Clinical Trials
Worse Outcomes Found Among Melanoma Patients Whose Brain Metastases Have BRAF V600E Alterations
Patients with melanoma brain metastases that have BRAF V600E alterations have worse outcomes, according to a new analysis appearing in JAMA Network Open.
Fianlimab Combined With Cemiplimab Elicits Durable Responses in Advanced Melanoma
In an interview with Targeted Oncology, Omid Hamid, MD, discussed the efficacy of fianlimab in combination with cemiplimab for advanced melanoma. The results of the study show new possibilities for treating patients who have failed adjuvant anti PD-1 therapy.
Follow-Up Study Confirms Safety, Efficacy of Neoadjuvant Immunotherapy in Resectable Cutaneous Melanoma
Study with longer follow-up confirms outcomes of neoadjuvant plus adjuvant programmed cell death receptor 1 (PD-1) inhibition with resection in patients with resectable stage III/IV cutaneous melanoma, according to a study recently published in the Annals of Oncology.